Westwood Holdings Group Inc. Has $2.09 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Westwood Holdings Group Inc. grew its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 18.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 53,102 shares of the company's stock after acquiring an additional 8,120 shares during the period. Westwood Holdings Group Inc. owned 0.06% of CRISPR Therapeutics worth $2,090,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Intellectus Partners LLC grew its position in CRISPR Therapeutics by 3.6% in the fourth quarter. Intellectus Partners LLC now owns 7,131 shares of the company's stock worth $281,000 after acquiring an additional 250 shares in the last quarter. Farrow Financial Inc. grew its position in CRISPR Therapeutics by 1.4% in the fourth quarter. Farrow Financial Inc. now owns 20,097 shares of the company's stock worth $777,000 after acquiring an additional 270 shares in the last quarter. Kestra Private Wealth Services LLC grew its position in CRISPR Therapeutics by 1.5% in the fourth quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company's stock worth $812,000 after acquiring an additional 310 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in CRISPR Therapeutics by 7.6% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company's stock worth $215,000 after acquiring an additional 372 shares in the last quarter. Finally, Horizon Kinetics Asset Management LLC grew its position in CRISPR Therapeutics by 4.3% in the fourth quarter. Horizon Kinetics Asset Management LLC now owns 10,682 shares of the company's stock worth $420,000 after acquiring an additional 443 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. The Goldman Sachs Group decreased their target price on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. TD Cowen raised shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price objective for the company in a report on Wednesday, February 12th. Morgan Stanley upped their price objective on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an "underweight" rating in a report on Friday, February 14th. Truist Financial upped their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Finally, Chardan Capital decreased their price objective on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $71.75.

CRISPR Therapeutics Stock Performance

Shares of CRSP stock traded down $0.67 during mid-day trading on Friday, reaching $36.86. The company's stock had a trading volume of 1,256,881 shares, compared to its average volume of 1,686,719. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $67.88. The company has a market cap of $3.18 billion, a P/E ratio of -8.43 and a beta of 1.88. The firm's 50-day moving average is $37.05 and its two-hundred day moving average is $42.00.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. During the same quarter last year, the firm posted ($1.43) earnings per share. The business's quarterly revenue was up 71.6% on a year-over-year basis. Sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Activity

In related news, CEO Samarth Kulkarni sold 9,973 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $423,054.66. Following the completion of the sale, the chief executive officer now owns 180,890 shares in the company, valued at $7,673,353.80. This trade represents a 5.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Julianne Bruno sold 1,198 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the sale, the chief operating officer now owns 8,263 shares of the company's stock, valued at $350,516.46. This trade represents a 12.66% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,021 shares of company stock worth $594,771. 4.30% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.